You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Gerhard Ries

Managing Partner at LifeCare Partners GmbH
Overview
Relationships
In The News
Paths
Education
Career History
Boards & Committees

Gerhard Ries

Managing Partner at LifeCare Partners GmbH

Overview

Age
49 (Born 1969)
Notable Companies
LifeCare Partners GmbH

BioMedPartners AG
Board Seats
22
Number of Relationships
This person is connected to 191 people.

Relationships See Details


Partner at LSP Management Group BV

Partner at VI Partners AG

Partner at BioMedPartners AG

Chief Executive Officer at Immunic AG

President at Haemosan, Inc.

Executive Director, Chief Executive Officer at Vectura Group Plc

Director-Stakeholders Board at European Vaccine Initiative

Chief Executive Officer & Director at EyeSense AG

Former Director at Lumavita AG

Partner at Omega Fund Management LLC
See 181 more listings with RelSci Professional.

In The News See More

AWP OTS (Original Text Service)
May 23, 2017
AWP OTS (Original Text Service)
December 3, 2015
PR Newswire
August 18, 2015
PR Newswire
July 27, 2015
PR Newswire
July 22, 2015
See full news coverage and complete stories with RelSci Professional.

Paths to Gerhard Ries

Gerhard Ries
You
Connections via Relationship Science
Gerhard Ries
Sync your contacts to see how you can connect with Gerhard Ries.

Educational Background

Ph.D Molecular Biology 
The University of Basel is the oldest university in Switzerland. Founded upon the initiative of local citizens in 1460, the University of Basel is a modern and attractive center of teaching, learning, and research situated in the heart of Basel. The University of Basel has been self-managed since 1996 whilst remaining under the jurisdiction of the Cantons of Basel-Stadt and Basel-Landschaft. It provides committed individuals from all over the world a strong academic community and an inspiring work environment. It employs nearly 3,500 people, and its annual budget is around CHF 550 million. The University of Basel is a classic university covering almost all fields of study from Ancient Studies to Zoology. The University of Basel is a rather small university in European standards with around 11,000 students, including 2,000 doctoral students (as of 2007). Around 320 professors and 1,300 lecturers provide an excellent education and encourage independent thinking and responsible action. The proportion of female students is 55% - and rising - and one of five students come from abroad. The University of Basel seeks top performance in research, teaching and service. For years, it is among the 100 best universities in the world, and in the German-speaking world it is one of the top ten.
Diploma in Biotechnology 

Career History

Managing Partner
2014 - Current
Director
Prior - 2014
Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development.
Co-Founder
2002 - 2014
BMP is a venture capital investment manager providing private equity and mezzanine financing to healthcare and human life science companies. The firm focuses on startups, young businesses and spinoffs in the biotechnology, emerging pharmaceuticals, medical technology and diagnostics sectors. They invest in Switzerland and neighboring countries.BioMedInvest is a venture capital fund invested in direct equity. BMP actively scouts for investment opportunities through their network of academic contacts. They target businesses with exceptional growth potential which are driven by distinctive technologies or offering services with unique advantages over current treatments. They generally participate in the first round of financing, either as the lead investor or through syndication with private equity firms and private individuals. The firm fosters the growth of their portfolio companies through management consulting and business support services. Their exit strategies include IPO and sale to leading pharmaceutical corporations or to strategic investors.BioMedInvest II LP is a venture capital fund focused on healthcare-related investments. The fund supports early-stage private firms as well as spin-offs active in segments such as emerging pharmaceutical, biotechnology, medical technology, diagnostics or platform technologies. They look for investments primarily in Switzerland, Germany and neighboring Western Europe. The fund typically invests in a range from CHF 1 million to CHF 10 million, as lead or co-lead investor.BioMedCredit is a mezzanine fund providing growth and expansion capital to small- and mid-size innovative businesses in Switzerland offering specialized services which may not have significant scaling-up potential. They focus on firms operating in products, technologies and services, specifically in the fields of biotechnology, emerging pharmaceuticals, analytical services, biomaterials, bioengineering, bioinformatics, down-stream processing, biotechnological platform technologies, chemical products and reagents, contract R&D and manufacturing, diagnostics, drug delivery technologies, lab technologies, automation, cell culture technologies as well as medical technology. The amount invested of the portfolio firms' lifetime ranges from CHF 0.5 million to CHF 5 million.
Partner
Prior
Project Manager
Prior
McKinsey & Co., Inc. provides management consulting services. Its areas of expertise include business technology, corporate finance, marketing and sales, operations, organizational risk and strategy planning, sustainability, and resource productivity. The firm offers advisory and analytical consulting solutions to commercial and industrial sectors such as electronics, aerospace, automotive, chemicals, media and entertainment, pharmaceuticals, medical, investment, telecommunications, transportation, and logistics. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.
Manager, Business Development
Prior
Novartis AG develops, manufactures, and markets healthcare products. It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, and Corporate Activities. The Pharmaceuticals segment provides patent-protected prescription medicines. The Alcon segment offers surgical, ophthalmic pharmaceuticals, and vision care products. The Sandoz segment supplies generic pharmaceuticals. The Corporate Activities segment includes other items of income and expense which are not attributable to specific segments such as certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations, and sponsorships. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Boards & Committees

Corporate Boards ▾
Member-Supervisory Board
2015 - Current
LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.
Member, Board of Directors
Current
Kuros Biosciences Ltd. engages in the development of products for tissue repair and regeneration. Its products include sealants for tissue restore and orthobiologics for bone healing. The company was founded by Didier Cowling and Jason Schense in 2000 and is headquartered in Schlieren, Switzerland.
Member, Board of Directors
Current
Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.
Member-Supervisory Board
Current
leon-nanodrugs GmbH develops oral and parenteral drugs. The firm's services include nanotechnology in medicine, MJR technology, pipeline, partnering with leon and leon network. The company was founded by Wolfgang Beier and Cornelia Beier in 2011 and is headquartered in Munich, Germany.
Director
Current
Immunic AG is a biotech company that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis. The company was founded by Andreas Mühler and Manfred Gröppel in April 2016 and is headquartered in Martinsried, Germany.
Member, Board of Directors
Current
Director
Current
Director
Current
Director
2015 - Prior
Kuros Biosurgery Holding AG discovers and develops drugs for biosurgery, tissue repair and regeneration. It operates as a medical technology company which engages in the development of biologic and biomaterial-based product candidates for localized therapy in trauma, spine and wound care. The company was founded by Marion Bavand, Didier Cowling, Dominik Ellenrieder, and Jeffrey Hubbel on April 3, 2008 and is headquartered in Zurich, Switzerland.^^
Chairman
Prior - 2014
Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland.
Director
Prior - 2014
Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development.
Member, Board of Directors
Prior
Affimed Therapeutics AG discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on their proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in May 2000 and is headquartered in Heidelberg, Germany.
Director
Prior
ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.
Director
Prior
Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.
Director-Executive Board
Prior
4-Antibody AG was discovers and develops drugs. The company was founded in 2002 and headquartered in Basel, Switzerland.
Director
Prior
Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.
Member, Board of Directors
Prior
GLYCART biotechnology AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.
Director
Prior
Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.
Member, Board of Directors
Prior
Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off fromESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications.
Director-Supervisory Board
Prior
Curetis AG operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany.
Member, Board of Directors
Prior
Lipomed AG develops, manufactures and markets pharmaceuticals and products for the treatment of rare diseases. The firm's products include alcohols, amphetamines and sympathomimetic amines, antidepressants, antipsychotics, barbiturates, benzodiazepines, cannabinoids, cathinones, cocaines, custom mixtures, hallucinogens, opioids, other cns depressants, steroids and vitamins. The company was founded in 1993 and is headquartered in Arlesheim, Switzerland.
Member, Board of Directors
Tenure Unconfirmed
EyeSense AG develops novel continuous blood glucose monitoring systems for diabetes patients. The firm's continuous glucose monitoring (CGM) gives a sense of security to diabetic patients. The company was founded by Achim Müller in 2006 and is headquartered in Basel, Switzerland.

Other Affiliations

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial
Still not convinced? Check out our full listing of features here.